Inmune Bio Inc (INMB)

Jupiter Neurosciences, Inc. (NASDAQ: $JUNS ), a B2i Digital Featured Company, recently presented at the Virtual Investor Conferences Life Sciences Investor Forum. In the clip below, President and CBO Alison Silva outlines the timeline for the company's Phase 2A Parkinson's disease study. View Clip Here: https://youtube.com/shorts/23IRp5Y6m_E Learn more about Jupiter Neurosciences at the B2i Digital Featured Companies profile: https://b2idigital.com/jupiter-neurosciences-1 "Our trial timelines are rapidly accelerating at this point. We are just activating our sites. We expect to enroll the first patient and subsequently dose the first patient. I'd say in the next few weeks here -- it's always hard to tell exactly when it's going to happen, but we've made significant progress in 2026. Again, it's 30 subjects and three months of dosing. We expect pretty concurrent enrollment. So as soon as we get all subjects in, we'll report out on that. And then it's three months of dosing and then probably about a two-month readout at the end of last patient last dose. So we hope to be announcing top-line results early next year, about 12 months from now. If all goes according to plan, we're very e xcited to be able to use the data from this trial to build out the pipeline and also move into a larger phase 2B or 3 in Parkinson's." In the full presentation, the company also discussed: • The JOTROL platform's 9x bioavailability advantage and the IP protecting it through 2036 • The 30-patient Phase 2A trial design at Georgetown University, including the panel of up to 22 biomarkers being assessed • What positive data could mean for pharma partnering discussions and pipeline expansion into Alzheimer's and MCI • The Nugevia direct-to-consumer longevity line as a commercial complement to the Parkinson's program Watch the complete presentation: https://www.virtualinvestorconferences.com/wcc/eh/4814904/lp/5271529/jupiter-neurosciences-inc-nasdaq-juns?utm_source=b2i&utm_medium=marketing&utm_campaign=0326LifeSciencesVIC Jupiter Neurosciences is led by Christer Rosén, Founder, Chairman and CEO; Alison Silva, President and CBO; Saleem Elmasri, CPA, CFO; and Marsh Hayward Ph.D., Co-Founder and CSO. To learn more about the company, visit www.jupiterneurosciences.com. For investor inquiries, contact [email protected]. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $INMB, $ANVS, $AVXL, $ATHA, $XBI

$INMB $LEMB $BIIB $INMB

$INMB $LLY $IWM

$INMB https://www.abstractsonline.com/pp8/#!/21436/presentation/8918

$INMB when will we see $ 3

$INMB https://www.inmunebio.com/index.php/newsroom/2026-news/muneioncnnouncesewreclinicalataat202620260416050504 $LLY $SPY $QQQ

$INMB To stretch its $24.8M runway to Q1 2027 [1], INmune Bio paused its two oncology platforms: INB03 and INKmune [2]. INB03 is the oncology version of their DN-TNF inhibitor (identical to XPro). INKmune is their natural killer cell-priming therapy [2]. By halting these and letting related Phase II licensing deadlines (like the Univ. of Pittsburgh agreement) expire [3], management drastically slashes its burn rate. This ensures remaining funds are funneled into survival priorities: the XPro Alzheimer's banking auction and CORDStrom regulatory filings to secure a Priority Review Voucher (PRV) [1,2]. Sources: [1] INMB FY25 10-K & Mar 30, 2026 PR [2] Q4 2025 Earnings Call Transcript [3] SEC Ex. 10.1 (Univ. of Pittsburgh License Amendment)

$INMB Progress on several programs and stock in the gutter ...... hhhmmm

$INMB like I said, this trash will go red today. Sell the news unfortunately. No one believes that bullshit release

$INMB 08:08 on Apr. 16 2026 INmune Bio To Present New Preclinical Data For Anti-Tumor Growth Treatment INB03; Data To Be Presented At The American Association For Cancer Research Annual Meeting On April 17-22 #tradeideas